First Time Loading...

Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 37.51 USD Market Closed
Updated: May 5, 2024
COLL
/
Income Statement
/
Revenue

Collegium Pharmaceutical Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Collegium Pharmaceutical Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Revenue
$566.8m
CAGR 3-Years
22%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$85.6B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$55.1B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$35.9B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
5%

Collegium Pharmaceutical Inc
Revenue Breakdown

Breakdown by Geography
Collegium Pharmaceutical Inc

Not Available

Breakdown by Segments
Collegium Pharmaceutical Inc

Total Revenue: 566.8m USD
100%
Represents Information Pertaining To Belbuca: 182.1m USD
32.1%
Represents The Information Pertaining To Xtampza: 177.4m USD
31.3%
Represents Information Pertaining To Nucynta Ir: 108.2m USD
19.1%
Represents Information Pertaining To Nucynta Er: 82.7m USD
14.6%
Represents Information Pertaining To Symproic: 16.5m USD
2.9%
Show More
Show Less

See Also

What is Collegium Pharmaceutical Inc's Revenue?
Revenue
566.8m USD

Based on the financial report for Dec 31, 2023, Collegium Pharmaceutical Inc's Revenue amounts to 566.8m USD.

What is Collegium Pharmaceutical Inc's Revenue growth rate?
Revenue CAGR 5Y
15%

Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Collegium Pharmaceutical Inc have been 22% over the past three years , 15% over the past five years .

ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.